Skip to main content
OpenTrials

Clinical trial condition

Moderate-to-severe Atopic Dermatitis

Explore clinical trials studying Moderate-to-severe Atopic Dermatitis. Study availability and eligibility vary by location and protocol.

24 public trials 6 recruiting studies
Refine in advanced search Browse all conditions

Moderate-to-severe Atopic Dermatitis trial results

Active, not recruiting

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

NCT03989206

Conditions
Moderate-to-severe Atopic Dermatitis
Locations
  • Galderma Investigational Site 8749 Birmingham, Alabama, United States
  • Galderma Investigational Site 8893 Birmingham, Alabama, United States
  • Galderma Investigational Site 8866 Guntersville, Alabama, United States
  • Galderma Investigational Site 8808 Scottsdale, Arizona, United States
View all 343 locations
View Trial Details
Completed

A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER)

NCT05899816

Conditions
Atopic Dermatitis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +10 more
Locations
  • Affiliated Dermatology Scottsdale, Arizona, United States
  • Center for Dermatology and Plastic Surgery Scottsdale, Arizona, United States
  • Scottsdale Clinical Trials Scottsdale, Arizona, United States
  • Medical Advancement Centers of Arizona Tempe, Arizona, United States
View all 85 locations
View Trial Details
Completed

Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

NCT04921345

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis, Atopic, +9 more
Locations
  • Galderma Investigational Site #8636 Fountain Valley, California, United States
  • Galderma Investigational Site #9937 San Diego, California, United States
  • Galderma Investigational Site #9930 Vista, California, United States
  • Galderma Investigational Site #9929 Coral Gables, Florida, United States
View all 23 locations
View Trial Details
Completed

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

NCT05590585

Conditions
Atopic Eczema, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, +14 more
Locations
  • Total Skin & Beauty Dermatology Center Birmingham, Alabama, United States
  • The University Of Alabama At Birmingham Birmingham, Alabama, United States
  • C2 Research Center, LLC Montgomery, Alabama, United States
  • Center for Dermatology Clinical Research, inc. Fremont, California, United States
View all 30 locations
View Trial Details
Completed

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03985943

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis, Atopic, +9 more
Locations
  • Galderma Investigational Site 8880 North Little Rock, Arkansas, United States
  • Galderma Investigational Site 8578 Cerritos, California, United States
  • Galderma Investigational Site 8636 Fountain Valley, California, United States
  • Galderma Investigational Site 8888 Fullerton, California, United States
View all 174 locations
View Trial Details
Completed

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

NCT03989349

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dermatitis, Dermatitis, Atopic, +9 more
Locations
  • Galderma Investigational Site 8749 Birmingham, Alabama, United States
  • Galderma Investigational Site 8893 Birmingham, Alabama, United States
  • Galderma Investigational Site 8866 Guntersville, Alabama, United States
  • Galderma Investigational Site 8808 Scottsdale, Arizona, United States
View all 138 locations
View Trial Details
Completed

A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China

NCT05017480

Conditions
Moderate-to-severe Atopic Dermatitis
Locations
  • Connect Investigative Site 33 Hefei, Anhui, China
  • Connect Investigative Site 01 Beijing, Beijing Municipality, China
  • Connect Investigative Site 02 Beijing, Beijing Municipality, China
  • Connect Investigative Site 03 Beijing, Beijing Municipality, China
View all 48 locations
View Trial Details
Completed

Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis

NCT05203380

Conditions
Moderate-to-severe Atopic Dermatitis
Locations
  • Clinical Research Center of Alabama, LLC Birmingham, Alabama, United States
  • Arizona Allergy & Immunology Research Gilbert, Arizona, United States
  • Pediatric Skin Research, LLC Coral Gables, Florida, United States
  • Skin Research of South Florida, LLC Miami, Florida, United States
View Trial Details

Related conditions